DYN

Dyne Therapeutics, Inc.

• Seeking Alpha·54m ago

  Biggest stock movers Tuesday: ZIM, NVS, and more

• Seeking Alpha·1h ago

  Novartis drops 13% on trial failure, dragging Dyne and Sarepta

• TipRanks·08/25 13:20

  Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Universal Health (UHS)

• TipRanks·08/17 11:36

  Dyne Maintained at Buy as Analyst Reaffirms $50 Price Target on Favorable DM1 Risk‑Reward Outlook

• NASDAQ·08/12 07:45

  Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH

• TipRanks·08/05 08:49

  Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

• TipRanks·08/04 02:10

  Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

• Dow Jones·07/31 17:41

  Dyne Therapeutics Price Target Cut to $45.00/Share From $47.00 by Morgan Stanley

• Dow Jones·07/31 17:41

  Dyne Therapeutics Is Maintained at Overweight by Morgan Stanley

• TipRanks·07/31 14:45

  Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley

• TipRanks·07/31 11:50

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Illumina (ILMN), Dyne Therapeutics (DYN) and Bristol-Myers Squibb (BMY)

• Dow Jones·07/30 17:53

  Dyne Therapeutics Is Maintained at Outperform by RBC Capital

• Dow Jones·07/30 17:53

  Dyne Therapeutics Price Target Raised to $35.00/Share From $30.00 by RBC Capital

• TipRanks·07/30 10:56

  Piper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

• NASDAQ·07/30 10:36

  Dyne Q2 Loss Widens As Phase 3 For DMD Therapy Progresses